CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be e...
Phase 3
Seoul, Korea, Republic of and 108 other locations
together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Part A - Dose Esca...
Phase 1
Seoul, Korea, Republic of and 27 other locations
monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). This study will also all...
Phase 1
Seoul, Korea, Republic of and 20 other locations
The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL wh...
Phase 3
Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of and 107 other locations
objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...
Phase 3
Seoul, Seoul Teugbyeolsi, Korea, Republic of and 230 other locations
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...
Phase 3
Seoul, Korea, Republic of and 179 other locations
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)...
Phase 3
Seoul, Seoul, Korea, Korea, Republic of and 231 other locations
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...
Phase 3
Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of and 216 other locations
This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in partici...
Phase 1, Phase 2
Seoul, Korea, Republic of and 48 other locations
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination wit...
Phase 3
Seoul, Korea, Republic of and 170 other locations
Clinical trials
Research sites
Resources
Legal